Respiratory Disease
Cystic fibrosis is the main therapeutic area in the sponsor’s clinical research, with a focus on chronic lung complications and infection-related disease burden.
- Pulmonary infection
- Chronic airway disease
- Respiratory microbiology
The clinical program centers on respiratory outcomes in people living with cystic fibrosis, particularly conditions affecting the lungs and persistent infection.
Antibacterial and Antimicrobial Therapy
The sponsor’s research activity includes therapies directed at Pseudomonas aeruginosa, reflecting interest in infection control within the cystic fibrosis setting.
- Pseudomonas lung infection
- Antimicrobial treatment
- Bacterial burden reduction
Attention is placed on managing persistent Pseudomonas colonization and its impact on respiratory health.
Phage-Based Therapeutics
Biomx Ltd. is involved in clinical research on bacteriophage-based approaches for infection-associated lung disease, with emphasis on targeted anti-bacterial activity.
- Phage therapy
- Targeted bacterial eradication
- Nebulized delivery
The research landscape includes inhaled treatment strategies designed for direct action in the airways.
Inhaled Pulmonary Drug Development
The sponsor’s trial activity reflects interest in nebulized therapies for localized treatment of lung infection in cystic fibrosis.
- Inhalation therapy
- Sputum bacterial load
- Airway-targeted treatment
This area focuses on therapies delivered directly to the respiratory tract to address infection within the lower respiratory tract.
